Core Laboratories (NYSE:CLB) is scheduled to release its earnings data after the market closes on Wednesday, April 25th. Analysts expect Core Laboratories to post earnings of $0.58 per share for the quarter. Core Laboratories has set its Q1 guidance at $0.56-0.58 EPS.
Core Laboratories (NYSE:CLB) last issued its earnings results on Wednesday, January 31st. The oil and gas company reported $0.58 EPS for the quarter, hitting the consensus estimate of $0.58. The company had revenue of $172.00 million during the quarter, compared to analyst estimates of $171.92 million. Core Laboratories had a return on equity of 58.25% and a net margin of 12.60%. The business’s revenue was up 15.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.41 EPS. On average, analysts expect Core Laboratories to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Shares of CLB opened at $122.74 on Tuesday. The company has a market capitalization of $5,365.96, a PE ratio of 61.37 and a beta of 1.40. The company has a quick ratio of 1.66, a current ratio of 1.98 and a debt-to-equity ratio of 1.53. Core Laboratories has a 52 week low of $86.55 and a 52 week high of $122.90.
A hedge fund recently raised its stake in Core Laboratories stock. The Manufacturers Life Insurance Company boosted its stake in shares of Core Laboratories (NYSE:CLB) by 63.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,128 shares of the oil and gas company’s stock after purchasing an additional 439 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Core Laboratories were worth $114,000 at the end of the most recent reporting period.
Several brokerages have recently commented on CLB. TheStreet upgraded Core Laboratories from a “c” rating to a “b-” rating in a research report on Thursday, February 1st. Zacks Investment Research upgraded Core Laboratories from a “hold” rating to a “buy” rating and set a $120.00 target price for the company in a research report on Wednesday, April 4th. ValuEngine upgraded Core Laboratories from a “sell” rating to a “hold” rating in a research report on Wednesday, April 11th. ABN Amro lowered Core Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th. Finally, Royal Bank of Canada set a $125.00 target price on Core Laboratories and gave the stock a “buy” rating in a research report on Tuesday, January 30th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $112.99.
About Core Laboratories
Core Laboratories N.V. provides reservoir description, and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates in two segments, Reservoir Description and Production Enhancement segments. The Reservoir Description segment comprises the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.
Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.